So should Apple provide you with an iPhone for free or at their cost, what about a carton of milk, is it moral to make a profit when providing a necessity for people's diet. What you are referring to is communism where everyone gets everything cheap and everyone makes the same low pay. The theory sounds nice but in reality it doesn't work versus capitalism in which companies charge what the market will bare. Society requires profitability (and in many cases large profitability) in order to motivate companies and the people within them to take risks thus advancing innovation. For every worldly successful drug created there are 20 that don't succeed that you'll never hear about, so the payoff has to worth while or the break through drug will never be developed in the first place.
He doesn't. I 'm not sure either but if I was to speculate I would say they will raise year guidance by at least $1B as they know last half will have incremental revenues from Japan and Brazil.
This lawsuit just doesn't make sense and seems fishy to me. We all know lawyers are leaches but they still require a lead platiff who has lost money in order to file a case. The only ones who have lost money over any significant period of time are shorts. I know shorts have been killed here but would someone scoop that low? Waste of their time and energy as they won't get a cent back for their efforts.
Glad you are able to recongize an opportunity when you see one. I assume you are covering your short and going long as a result of this recent pull back, atta boy.
I think that decline today is more related to the Health Care Co. amalgamating but that will not change GILDs future ability to maitain current price level, which I believe may investers are thinking will happen.
It dropped to that level likely because of your stop. Did it get taken out. hope not.
BIIB news is bad for BIIB but GILD's drugs are not related so a 4% decline in GILD is way overdone. Also BIIB's PE is 28+ and GILD is 12-13 range, so GILD is less then half it's price and now looks as if it's growth will be stronger then BIIBs.
AMAG would be up over $74 if BIIB hadn't of killed the biotech index today. IBB down 2% AMAG up over 1%. Hold this until at least a double. Will wait until EOD to see what happens and if AMAG weakens will buy
If numbers are good as I expect, all todays slide will do is add fuel to next week's earnings rally.
Actually this should have a PE of at least 40 (well below average for pharma/biotech's with this kind of growth) giving it a stock price of $219. I'm getting deja vu as I traded stocks like JAZZ when it was $70 and Questcor (QCOR) when it was $40 and similiar games where played. I remember they were volitile and difficult to trade as well. QCOR would have bear raids that would bring it down 10% in a morning and JAZZ would be up $3 in the morning then fall $2 in the afternoon, and I actually don't think either of those biotechs were nearly as strong as AMAG at that time. They both had only 1 drug making revenues and yet QCOR's PE was in the 50-70s and JAZZ's was over 100. These stocks have both more then doubled since then (QCOR was bought out at $92). The key is to buy on these dips and don't watch it every minute has there is too much of a temptation to panic sell, exactly what the MMs want. Today they used a undeserved negative headline and weak afternoon market to drive the price down and pick up cheaper shares. Hold onto your shares and don't sell until at least a double.
So the big money will wait for this selling to ease before entering.
Something is going on????
Looking to hold these shares until $99
It's the last minute that tells the story and that went from .30 to .54 which isn't down much from the days average price. There is always nervousness going into earnings and many sell even if good earnings are expected, to reduce risk. Of course if numbers are better then expected and they increase yearly guidance as I expect then they will be buying back in at higher prices.
I believe it's just a retracement from highs as many take profit before earnings. I'd rather have it that way then a run up into earnings as we just had with Apple.
The latest aquisition will allow them to raise yearly guidance tomorrow on earnings calls.
Gilead didn't run like Apple, Facebook etc. during this last tech rally so will Apple's earnings disappointment (although it was in line) bring Gilead and other biotech's down?
ICPT is no Pharmasset. GILD's early stage NASH results have been better then ICPTs so why would they purchase them?